MYH2 and prostate cancer: Our results indicate that activation of GPER in both pancreatic and prostate cancer cells inhibits these mechanical properties via the protein kinase A–RhoA–myosin-2 axis and concurrently inhibits pancreatic cancer cell invasion through an in vitro basement membrane (Figure 7).